tbuckley/cabot-search huggingface dataset:
CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dimCD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial
Authors: Roman M. Shapiro, Michal Sheffer, Matthew Aaron Booker, Michael Yevgeniy Tolstorukov, Michela Ansuinelli, Moshe Sade-Feldman, Jacy Fang, Grace Caroline Birch, Juliana Vergara-Cadavid, Yasmin Z Abdulhamid, Isabel E Kaplan, Dinh Khanhlinh, Robert A. Redd, Alejandro Alonso, Denbaa Bat-Erdene, Ravindra Uppaluri, Heather Daley, Diego Hernandez Rodriguez, John Koreth, Jerome Ritz, Sarah Nikiforow, Robert J. Soiffer, Glenn J Hanna, Rizwan Romee
Journal: Blood (2023)
Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience
Authors: Idanna Innocenti, Annamaria Tomasso, Antonio Mosca, Michela Colalelli, Giulia Benintende, Eugenio Galli, Patrizia Chiusolo, Elisabetta Metafuni, Sabrina Giammarco, Federica Sorà, Maria Assunta Limongiello, Alberto Fresa, Luca Stirparo, Fabio Lamberti, Francesco Autore, Andrea Bacigalupo, Stefan Hohaus, Valerio De Stefano, Simona Sica, Luca Laurenti
Journal: Blood (2023)
Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes
Authors: Luana Fianchi, Alfonso Piciocchi, Chiara Cattaneo, Fabio Guolo, Francesco Marchesi, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi, Crescenza Pasciolla, Olimpia Finizio, Nicola Fracchiolla, Mario Delia, Federica Lessi, Michelina Dargenio, Valentina Bonuomo, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Picardi, Claudia Basilico, Monica Piedimonte, Paola Minetto, Marianna Criscuolo, Matteo Bonanni, Patrizia Chiusolo, Lucia Prezioso, Caterina Buquicchio, Lorella Maria Antonia Melillo, Daniele Zama, Francesca Farina, Antonio Giordano, Valentina Mancini, Irene Terrenato, Michela Rondoni, Andrea Bacigalupo, Alessandro Busca, Livio Pagano
Journal: Blood (2023)
Incidence of Secondary Primary Malignancies after Long-Term Follow up of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation - Report from Croatian Cooperative Group for Hematologic Malignancies (KroHem)
Authors: Josip Batinic, Barbara Dreta, Delfa Radić-Krišto, Davor Galusic, Jasminka Sinčić Petričević, Hrvoje Holik, Ivan Krecak, Martina Morić Perić, Ivan Zekanović, Mario Piršić, Ozren Jakšić, Goran Rinčić, Toni Valković, Dubravka Sertić, Ranka Serventi Seiwerth, Pavle Rončević, Ines Bojanić, Petra Berneš, Ilenia Romić, Sanja Mazić, Sandra Bašić-Kinda
Journal: Blood (2023)
Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes
Authors: Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades
Journal: Blood (2023)
Association between Microenvironment-Related Genes and Prognosis of Primary Central Nervous System Lymphoma
Authors: Keiichiro Hattori, Kenichi Makishima, Naoki Kurita, Yoshiaki Abe, Mamiko Sakata-Yanagimoto, Tatsuhiro Sakamoto, Sakurako Suma, Yasuhito Suehara, Ryota Matsuoka, Daisuke Matsubara, Motoo Nagane, Ryota Ishii, Ryo Nishikawa, Shota Tanaka, Akitake Mukasa, Yoshitaka Narita, Koichi Ichimura, Shingo Takano, Eiichi Ishikawa, Shigeru Chiba
Journal: Blood (2023)
Quantitative System Pharmacology Modeling of the Effect of Recombinant ADAMTS13 on Platelets in Patients with Congenital Thrombotic Thrombocytopenic Purpura
Authors: Cameron McBride, Jiaolong Jiang, Zhiwei Zhang, John Tolsma, Björn Mellgård, Majid Vakilynejad, Indranil Bhattacharya, Andy Zhu
Journal: Blood (2023)
Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis
Authors: Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel
Journal: Blood (2023)
Safety of Total Skin Electron Therapy with Concurrent Systemic Therapy
Authors: Monica Chelius, Leah Cohen, Cecilia Jiang, John Mallon, Justin Greisz, Ann Tierney, Nasheed Hossain, Alain Rook, Jennifer Villasenor-Park, Sara Samimi, Ellen Kim, John Plastaras, Stefan K. Barta, Michael Lariviere
Journal: Blood (2023)
Retinoic Acid and Ascorbate Remodel the Epigenome of Leukemia Cells to Improve Therapeutic Efficacy By Enhancing TET Activity
Authors: Tiffany Leesang, Yoon Sing Yap, John P Brabson, Abigail Klimas, Emily L Ahearn, Daniela A Barbieri, Minh Quang Lam, Peter D Lyon, Maria Ken E. Figueroa, Felipe Beckedorff, Luisa Cimmino
Journal: Blood (2023)
Outcomes in Acute Lymphoid Leukemia Patients with Incomplete Hyper-CVAD Cycles
Authors: Sabrina Matosz, Meaghan Standridge, Danielle Bradshaw, Amany R. Keruakous, Jorge Cortes, Mohammad Mian, Locke Johnson Bryan, Anand Jillella, Ayushi Chauhan, Vamsi K. Kota
Journal: Blood (2023)
A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies
Authors: Anastasiya Yudina, Anastasiya Danchurova, Lolita Alekseeva, Aleksei Efremov, Sergei Starikov, Danielle Sookiasian, Ekaterina Nuzhdina, Svetlana Podsvirova, Madison Chasse, Tori Conroy, Noel English, Dmitry Tabakov, Sheila T. Yong, Artur Baisangurov, Cagdas Tazearslan, Nathan Fowler, Alexander Bagaev
Journal: Blood (2023)
Effectivness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China
Authors: Kaiyang Ding, Yue-Xin Cheng, Xiaoyong Wang, Chen Huang, Yang Liang, Wei Li, Jingjing Ye, Chunyan Ji
Journal: Blood (2023)
A self-assembled graphene oxide adjuvant induces both enhanced humoral and cellular immune responses in influenza vaccine
Authors: Shiyi Huang, Yiyang Li, Shuang Zhang, Youming Chen, Wenqiong Su, David J. Sanchez, John D.H. Mai, Xiao Zhi, Hongjun Chen, Xianting Ding
Journal: Journal of Controlled Release (2023)
Peripherally Inserted Central Catheter Safety and Efficacy in Acute Lymphoblastic Leukemias: A 16-Years Monocentric Experience
Authors: Daniele Derudas, Sabrina Chiriu, Claudio Romani, Federica Pilo, Martina Pettinau, Giuseppe Longhitano, Daniela Ibba, Loredana Aracu, Giorgio La Nasa
Journal: Blood (2023)
Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b <i>In Vivo</i>
Authors: Valerio Ciaurro, Marina Y. Konopleva, Naval Daver, Anna Skwarska, Maria Paola Martelli
Journal: Blood (2023)
Risk-Adapted Donor Lymphocyte Infusion after Hematopoietic Cell Transplant in Pediatric and Young Adult Patients Is Associated with Low Risk of Graft Versus Host Disease
Authors: Shruthi Suryaprakash, Yilun Sun, Li Tang, Dinesh Keerthi, Amr Qudeimat, Aimee C. Talleur, Ewelina K. Mamcarz, Ashok Srinivasan, Madden Renee, Rebecca Epperly, Swati Naik, Stephen Gottschalk, Brandon M Triplett, Akshay Sharma
Journal: Blood (2023)
Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Authors: Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood (2023)
Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Authors: Sushma Bharadwaj, Eric Lau, Anmol Goyal, Mark P. Hamilton, Hrishikesh Srinagesh, Alexandria Jensen, Shriya Syal, Jayasindhu Mallampet, Theresa Latchford, Bita Sahaf, Wen-Kai Weng, Melody Smith, Holden T Maecker, Matthew J. Frank, David B. Miklos, Saurabh Dahiya
Journal: Blood (2023)
Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia
Authors: Arliene Ravelo, Kelley Myers, Claire Ervin, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S Manzoor, Juliana M. L. Biondo, Carol Mansfield
Journal: Blood (2023)
Red Blood Cell Pyruvate Kinase Properties in Sickle Cell Disease - of Mice and Men
Authors: Marissa J.M. Traets, Brigitte A. van Oirschot, Titine J.J. Ruiter, Charles Levine, Anita W. Rijneveld, Judith J.M. Jans, Minke A.E. Rab, Yu-Wei Chen, Richard van Wijk
Journal: Blood (2023)
Feasibility and Implementation of an out-of-Pocket Cost Calculator for Pre-Treatment Financial Counselling in Cancer Patients
Authors: Maggie Wong, Zhi Yao Chan, Mei Yin Quek, Alexis Koh, Constance Teo, Jinny Foo, Cheng Ean Chee, Andrea Wong, Samuel Ow, Joey Tay, Vivian Luah, Xiao Shi Saw, Yuet Peng Wong, Meng Tuck Lee, Jolene Lee, Chee-Yen Lin, Wei-Ying Jen, Wee-Joo Chng, Janelle Chua
Journal: Blood (2023)
A Novel Approach to Epigenetic Profiling in Acute Myeloid Leukemia: Mapping Methylation and Hydroxymethylation in Genomic and Cell-Free DNA
Authors: Miriam Neaman, Mika Bell, Jasline Deek, Irit Avivi Mazza, Yakir Moshe, Yael Michaeli, Noa Gilat, Gal Mesika Surizon, Topaz Kreiser Shem Tov, Metsada Pasmanik Chor, Yuval Ebenstein
Journal: Blood (2023)
Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia
Authors: Lining Zhang, Jianping Li, Weiru Liang, Jialin Wei, Yi He, Erlie Jiang, Fengkui Zhang, Mingzhe Han, Sizhou Feng
Journal: Blood (2023)
Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies
Authors: Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida
Journal: Blood (2023)
Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Authors: Huijuan Fan, Zhanao Xu, Ke Yao, Bingxin Zheng, Yuan Zhang, Xuxiang Wang, Tengjiang Zhang, Xuan Li, Haitian Hu, Bin Yue, Zeping Hu, Hanqiu Zheng
Journal: Cancer Research (2023)

Abstract The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies. Significance: Metabolic interaction between osteoclasts and tumor cells contributes to resistance to DNA-damaging agents, which can be blocked by combination treatment with PARP and osteoclast inhibitors to reduce bone metastatic burden.
Exon-specific oncogenic function of the long noncoding RNA plasmacytoma variant translocation 1 in cutaneous squamous cell carcinoma: a promising potential therapeutic target
Authors: Max Bone, Gareth J Inman
Journal: British Journal of Dermatology (2023)

Journal Article Corrected proof Exon-specific oncogenic function of the long noncoding RNA plasmacytoma variant translocation 1 in cutaneous squamous cell carcinoma: a promising potential therapeutic target Get access Max Bone, Max Bone Writing - original draft, Writing - review & editing Cancer Research UK Scotland Institute and School of Cancer Sciences, University of Glasgow, Glasgow, UK Search for other works by this author on: Oxford Academic Google Scholar Gareth J Inman Gareth J Inman Writing - original draft, Writing - review & editing Cancer Research UK Scotland Institute and School of Cancer Sciences, University of Glasgow, Glasgow, UK Correspondence: Gareth Inman. Email: gareth.inman@glasgow.ac.uk https://orcid.org/0000-0002-6264-4253 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad476, https://doi.org/10.1093/bjd/ljad476 Published: 01 December 2023 Article history Received: 19 November 2023 Accepted: 23 November 2023 Published: 01 December 2023 Corrected and typeset: 23 January 2024
Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for &amp;gt; 24 Hours
Authors: Zachary David Crees, Keith Stockerl-Goldstein, Ella Sorani, Debby Ickowicz, Liron Darvish, John F. DiPersio
Journal: Blood (2023)
Age-Based Comparison of Dara-Rvd, Krd and Rvd Induction Therapies during the First Line of Therapy for Multiple Myeloma Patients
Authors: Jennifer M. Ahlstrom, Patricia Alejandra Flores Pérez, Felipe Flores Quiroz, Karla Mariana Castro Bórquez, Mason S. Barnes, Jay R. Hydren, Jorge Arturo Arturo Hurtado Martinez
Journal: Blood (2023)
Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Authors: Xavier Leleu, Thomas Delea, Patricia Guyot, Aaron Moynahan, Erin Singh, Christina Tekle, Peggy L Lin
Journal: Blood (2023)
Haploidentical Donor Transplants with Cytokine Release Syndrome Have Increased Risk of Clinically Significant Early CMV Reactivation Compared with Matched Donor Transplants Receiving Post-Transplant Cyclophosphamide
Authors: James Schwarer, Joanne BL Tan, BIanca Cirone, Lily Rush, Jenny Muirhead, Shu Min Wong, Shafqat Inam, Shaun Fleming, Sushrut S. Patil, C. Orla Morrissey, John Coutsouvelis, Andrew Spencer, David J. Curtis
Journal: Blood (2023)
Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment
Authors: Signy Chow, Alexandra Misura, Olga Bigun, Sila Usta, Renato Sasso, Dylan Gowlett-Park, Katarina Czibere, Rena Buckstein, Lee Mozessohn, Lisa Chodirker, James Kennedy, Hubert Tsui
Journal: Blood (2023)
Statin Use and Its Effects on Survival Outcomes and Rates of Gvhd in Allogeneic Stem Cell Transplant Patients: Results from Real-World Cohorts
Authors: Jacob Fuqua, Abdulrahman Abonofal, Danish Safi, Maimoona Khan, Hiba Khan, Spencer Yingling, Salah Ud Din Safi
Journal: Blood (2023)
Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel)
Authors: Alexis A. Thompson, Timothy S. Olson, Mark C. Walters, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E. J. Rasko, Evangelia Yannaki, Shamshad Ali, Gloria Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski
Journal: Blood (2023)
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Authors: Kadiatou Traore, Alankrita Taneja, Elan Gorshein, Francesca Castro, Andriy Derkach, Jorge Arturo Hurtado Martinez, Edith Serrano, Alexander Lesokhin, Jennifer M. Ahlstrom, Torin Block, Jay R. Hydren, Saad Z Usmani, Urvi A Shah
Journal: Blood (2023)
The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia
Authors: Elena Kuzmina, Ekaterina Chelysheva, Elza Lomaia, Elena V Morozova, Oleg Shukhov, Anna Petrova, Tamara Chitanava, Julia Vlasova, Evgenia Sbitiakova, Natalia Lazorko, Irina Nemchenko, Anastasiya Vitalievna Bykova, Margarita Gurianova, Alina Kokhno, Anna Turkina
Journal: Blood (2023)
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
Authors: Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter
Journal: Blood (2023)
Statewide Burden and Trends of Acute Myeloid Leukemia in the United States between 1990-2019: A Benchmarking Analysis for the Global Burden of Disease Study 2019
Authors: Dhruvkumar Gadhiya, Parjanya Bhatt, Cleris Christian, Gauravdeep Singh, Arushi Dhawan, Vishrant Amin, Juhi Patel, Hardik Dineshbhai Desai
Journal: Blood (2023)
Different Sources of Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: Relationship between Immune Reconstitution, Graft-Versus-Host Disease, and Viral Infections
Authors: Jianyun Liao, Chaoke Bu, Lan He, Huaying Liu, Zhiyong Peng, Weiwei Zhang, Haoran Tang, Jing Wang, Zimao Lu, Yanfeng Zhou, Yuqian Xia, Yuelin He, Chunfu Li
Journal: Blood (2023)
Venous Thromboembolism in Total Hip and Total Knee Arthroplasty
Authors: Samantha J. Simon, Rushad Patell, Jeffrey I. Zwicker, Dhruv S. Kazi, Brian L. Hollenbeck
Journal: JAMA Network Open (2023)

Importance The optimal pharmacologic thromboprophylaxis agent after total hip and total knee arthroplasty is uncertain and consensus is lacking. Quantifying the risk of postoperative venous thromboembolism (VTE) and bleeding and evaluating comparative effectiveness and safety of the thromboprophylaxis strategies can inform care. Objective To quantify risk factors for postoperative VTE and bleeding and compare patient outcomes among pharmacological thromboprophylaxis agents used after total hip and knee arthroplasty. Design, Setting, and Participants This retrospective cohort study used data from a large health care claims database. Participants included patients in the United States with hip or knee arthroplasty and continuous insurance enrollment 3 months prior to and following their surgical procedure. Patients were excluded if they received anticoagulation before surgery, received no postsurgical pharmacological thromboprophylaxis, or had multiple postsurgery thromboprophylactic agents. In a propensity-matched analysis, patients receiving a direct oral anticoagulant (DOAC) were matched with those receiving aspirin. Exposures Aspirin, apixaban, rivaroxaban, enoxaparin, or warfarin. Main Outcomes and Measures The primary outcome was 30-day cumulative incidence of postdischarge VTE. Other outcomes included postdischarge bleeding. Results Among 29 264 patients included in the final cohort, 17 040 (58.2%) were female, 27 897 (95.2%) had inpatient admissions with median (IQR) length of stay of 2 (1-2) days, 10 948 (37.4%) underwent total hip arthroplasty, 18 316 (62.6%) underwent total knee arthroplasty; and median (IQR) age was 59 (55-63) years. At 30 days, cumulative incidence of VTE was 1.19% (95% CI, 1.06%-1.32%) and cumulative incidence of bleeding was 3.43% (95% CI, 3.22%-3.64%). In the multivariate analysis, leading risk factors associated with increased VTE risk included prior VTE history (odds ratio [OR], 5.94 [95% CI, 4.29-8.24]), a hereditary hypercoagulable state (OR, 2.64 [95% CI, 1.32-5.28]), knee arthroplasty (OR, 1.65 [95% CI, 1.29-2.10]), and male sex (OR, 1.34 [95% CI, 1.08-1.67]). In a propensity-matched cohort of 7844 DOAC-aspirin pairs, there was no significant difference in the risk of VTE in the first 30 days after the surgical procedure (OR, 1.14 [95% CI, 0.82-1.59]), but postoperative bleeding was more frequent in patients receiving DOACs (OR, 1.36 [95% CI, 1.13-1.62]). Conclusions and Relevance In this cohort study of patients who underwent total hip or total knee arthroplasty, underlying patient risk factors, but not choice of aspirin or DOAC, were associated with postsurgical VTE. Postoperative bleeding rates were lower in patients prescribed aspirin. These results suggest that thromboprophylaxis strategies should be patient-centric and tailored to individual risk of thrombosis and bleeding.
Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy
Authors: Taylor K Mandeville, Cory Mavis, Juan Gu, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2023)
The Impact of a Virtual Platform to Reduce Hematology-Oncology Educational Disparities Amongst Healthcare Professionals in Lower Socioeconomic Regions Globally
Authors: Yan Leyfman, Gayathri P. Menon, Muskan Joshi, Maduri Balasubramanian, Keira P. Smith, Elizabeth J. Heller, Helena S. Coloma, Alexandra Van de Kieft, Ahmed Hashim, Harshal Chorya, Rabab H. Abbas, Gabriele Alves, Jenna Ghazal, Steven Wilson, Shane Grivna, Chandler Howard Park
Journal: Blood (2023)
Characterization of markers, functional properties, and microbiome composition in human gut-derived bacterial extracellular vesicles
Authors: Chih-Chi Li, Wei-Fan Hsu, Po-Chieh Chiang, Ming-Che Kuo, Andrew M. Wo, Yufeng Jane Tseng
Journal: Gut Microbes (2023)

Past studies have confirmed the etiologies of bacterial extracellular vesicles (BEVs) in various diseases, including inflammatory bowel disease (IBD) and colorectal cancer (CRC). This study aimed to investigate the characteristics of stool-derived bacterial extracellular vesicles (stBEVs) and discuss their association with stool bacteria. First, three culture models – gram-positive (G+)BcBEVs (from B.coagulans), gram-negative (G-)EcBEVs (from E.coli), and eukaryotic cell-derived EVs (EEV, from Colo205 cell line) – were used to benchmark various fractions of stEVs separated from optimized density gradient approach (DG). As such, WB, TEM, NTA, and functional assays, were utilized to analyze properties and distribution of EVs in cultured and stool samples. Stool samples from healthy individuals were interrogated using the approaches developed. Results demonstrated successful separation of most stBEVs (within DG fractions 8&9) from stEEVs (within DG fractions 5&6). Data also suggest the presence of stBEV DNA within vesicles after extraction of BEV DNA and DNase treatment. Metagenomic analysis from full-length (FL) region sequencing results confirmed significant differences between stool bacteria and stBEVs. Significantly, F8&9 and the pooled sample (F5-F9) exhibited a similar microbial composition, indicating that F8&9 were enriched in most stBEV species, primarily dominated by Firmicutes (89.6%). However, F5&6 and F7 still held low-density BEVs with a significantly higher proportion of Proteobacteria (20.5% and 40.7%, respectively) and Bacteroidetes (24% and 13.7%, respectively), considerably exceeding the proportions in stool and F8&9. Importantly, among five healthy individuals, significant variations were observed in the gut microbiota composition of their respective stBEVs, indicating the potential of stBEVs as a target for personalized medicine and research.